Precision Medicine, AI, and Global Collaboration in Cancer Care Take Center Stage in Berlin
Dr. Christina Ng Van Tze, a respected Consultant Medical Oncologist and Medical Director at Onco Life Centre in Bangsar South, Kuala Lumpur, recently represented Malaysia at the ESMO Congress 2025 in Berlin. The global event brought together oncology leaders to showcase the latest advancements in cancer care. As the Founder President of Empowered – The Cancer Advocacy Society of Malaysia, Dr. Ng provided key insights into how Malaysia is embracing innovation in personalized treatment.
“It was an honor to stand alongside global experts committed to better patient outcomes,” Dr. Ng said. “Representing Onco Life Centre at ESMO was both inspiring and affirming.”
A Global Movement Toward Precision Cancer Care
ESMO 2025 gathered thousands of oncology professionals to discuss the latest breakthroughs in cancer research and treatment. This year, the focus was clear. Precision medicine dominated the conversation, with advancements in molecular profiling, AI diagnostics, and cancer genetics taking center stage. These developments closely mirror Onco Life Centre’s approach, where treatment is guided by tumor biology and each patient’s unique profile.
Dr. Ng emphasized that understanding the individual tumor using tools such as genomic sequencing, radiomic analyses, and circulating tumor DNA (ctDNA) is quickly becoming the global standard. She added, “These technologies support our commitment to delivering tailored, science-based care in Malaysia.”
Scientific Insights That Could Transform Local Practice
One of the most impactful sessions at ESMO 2025 covered the evERA BC trial. This study examined the use of giredestrant, an oral SERD, in combination with everolimus for patients with hormone receptor-positive breast cancer. The results were especially promising for those with ESR1 mutations who had progressed after CDK4/6 inhibitor therapy. This combination may soon become an essential component in managing advanced breast cancer conditions, especially in Malaysia, where many patients are diagnosed at a younger age or present with aggressive tumors.
Sessions focused on thoracic oncology also stood out. Experts shared updates on ALK-targeted treatments, AI-supported pathology tools, and the use of ctDNA in guiding therapy for lung cancer. This disease is becoming more prevalent in Malaysia, especially among non-smokers and women. These innovations could significantly improve outcomes in patients with cancer spread to the lungs, bones, distant nodes, and chest wall.
Integrating AI into Clinical Practice
Artificial intelligence was a recurring theme throughout the congress. Researchers demonstrated how AI tools can analyze imaging and genetic data to identify patients who are most likely to respond to targeted therapies or immunotherapy. These models allow clinicians to avoid ineffective treatments and offer more effective options earlier in the care process.
“At Onco Life Centre, we are already integrating digital platforms to improve diagnostics and patient monitoring,” said Dr. Ng. “Seeing global validation of these technologies reinforces that we are moving forward with confidence.”
AI’s role also extends to predicting cancer progression to organs such as the liver, lungs, and distant nodes, helping oncologists design more proactive treatment strategies.
Showcasing Malaysian Oncology on the International Stage
Dr. Ng participated in multiple in-depth conversations with global peers, discussing challenges such as unequal access to molecular testing, variability in treatment availability, and the lack of robust psycho-oncology services. She shared how Malaysia is tackling these issues through advocacy and education while investing in more accessible diagnostics and support systems.
“These exchanges affirmed the progress we’ve made, but also opened new ideas for how we can improve,” she noted. Topics also included how to prevent total bowel blockage in late-stage patients and improve care for those who are entirely oxygen dependent or undergoing mastectomy.
Post-ESMO Action Plan at Onco Life Centre
Following ESMO 2025, Dr. Ng and her team plan to accelerate several initiatives aimed at improving local cancer care:
Increase access to molecular profiling for breast, lung, and GI cancers
Expand ctDNA testing for better-informed treatment choices
Enhance multidisciplinary team discussions for complex cases
Invest in psycho-oncology and supportive care services
Educate patients and families with clearer, more personalized guidance
“Every technical advancement must serve a human purpose,” Dr. Ng said. “That is our core philosophy at Onco Life Centre.”
Building a Future of Collaboration and Compassion
Dr. Ng’s presence at ESMO 2025 reaffirmed her commitment to global collaboration and ongoing learning. As the primary oncologist, Dr. Christina continues her work both at the clinic and through her advocacy platform, Empowered. She remains focused on making global innovations accessible at home.
Patients who have consulted Dr. Christina Ng at Onco Life Centre in Bangsar South KL often praise the centre’s comprehensive approach, which includes regular follow-up for surveillance, recommendations for specific genomics tests, and compassionate care even in the most complex cases involving the liver, lungs, bones, skin, or distant nodes.
For more information or to book an appointment, contact Onco Life Centre today to learn about cutting-edge treatments, including promising therapies such as antibody-drug conjugates.
